Table 2.
Variable | Overall | Urban sites | Rural sites |
---|---|---|---|
Total specimens eligible for genotyping, n | 379 | 249 | 130 |
Total successfully genotyped, n | 321 | 205 | 116 |
Genotyping rate, % | 85 | 82 | 89 |
HIVDR in all initiators, n | 321 | 205 | 116 |
any DRM, % (95% CI) | 10.4 (5.4–19.1) | 14.2 (6.6–27.9) | 4.3 (1.2–14.3) |
PI DRMs, % (95% CI) | 0.3 (0.1–1.5) | 0.5 (0.1–2.6) | 0 |
NRTI DRMs, % (95% CI) | 2.4 (0.4–12.9) | 3.9 (0.6–20.9) | 0 |
NNRTI DRMs, % (95% CI) | 10.0 (5.1–18.8) | 13.7 (6.2–27.5) | 4.3 (1.2–14.3) |
HIVDR in initiators with no prior exposure to ARVs | 223 | 141 | 82 |
any DRM, % (95% CI) | 10.4 (4.7–21.5) | 13.5 (5.1–31.5) | 5.3 (1.4–17.5) |
PI DRMs, % (95% CI) | 0.3 (0.0–2.1) | 0.5 (0.1–3.7) | 0 |
NRTI DRMs, % (95% CI) | 2.8 (0.4–16.3) | 4.6 (0.7–26.2) | 0 |
NNRTI DRMs, % (95% CI) | 10.1 (4.4–21.3) | 13.1 (4.7–31.2) | 5.3 (1.4–17.5) |
HIVDR in initiators with prior exposure to ARVs, n | 29 | 23 | 6 |
any DRM | 14.7 (4.6–38.2) | 18.8 (5.5–48.0) | 0 |
PI DRMs | 1.1 (0.1–8.8) | — | — |
NRTI DRMs | 1.6 (0.2–9.9) | — | — |
NNRTI DRMs | 13.6 (3.9–37.9) | — | — |
—, not displayed.
Data are presented as n, % or study design-weighted proportion [% (95% CI)].